My questions have been asked by some of the above, but I am assuming you will be posting the answers you receive.

tykerb/avastin trial
 

I know there is an Tykerb/Avastin trial open at UCSF under the direction of Dr. Hope Rugo. It just opened last week or so. I imagine there are others around.

You can call the study coordinator:
> Jacqueline Lyandres, MS
> Clinical Research Coordinator
> University of California, San Francisco
> 1600 Divisadero Street
> 6th Floor, Room B612
> San Francisco, CA 94115
> tel: 415.353.7857
> fax: 415.353.9651

Your doctor can also give this combo to you directly.

Hi, Just joined the recurrence on a recurrence group this week!! (Damn!!).

I have a small pleural effusion, and wanted to go on Tykerb, however, the EAP states that I must have progressed whilst on Herceptin and Taxol. I don't tolerate Taxol well at all (from adjuvant experience). Is there any other chemo drug (preferrably one where my hair doesn't fall out) that I can go on. Will there be a cut off either of patient numbers or a time limit for the EAP in Australia?
Cheers
Roz

what is the best protocol in adjuvant setting for non metastatisc BC :

Tykerb/Xeloda after Herceptin OR Tykerb/Xeloda with Herceptin

Hi Joe - like Caya - would like to know how to get access to Tykerb for EBC outside the US - ie in Australia (stage 11B) - can I get access if I travel to the US? Otherwise I gather it will take several more years for the drug to be listed. thanks for taking on our questions -cheers - B

When will Tykerb be approved for sale in India and Canada?

Thanks, Joe. I think this may be Chrissy question, but:
For women who had positive node (s) but no mets, have finished a year of herceptin and are currently NED -- any trials to test returning to treatment on Tykerb for prevention of future recurrance?
THANK YOU
Linda

Thanks for doing this, Joe. My questions concern off-label usage, but I will still be watching this thread for the answers they are able to provide.

Val

Eligibility Restrictions
 

First, I want to thank you for taking these questions. My sister's oncologist at Memorial Sloan Kettering told us she would not be eligible for Tykerb because she was on Xeloda before ( or Zometa before ). She has advanced liver mets that have stopped responding to any other drugs ( Herceptin, Avastin) and we are out of options. They cannot operate either because of the location of the tumor. She has fought so hard to make it to the Tykerb approval date so we were devastated to hear that she would not be eligible. Tykerb is really our last hope. I am hoping that either her oncologist is mistaken or we misunderstood.

Does anyone know of any eligiblity restrictions?

THANKS SO MUCH!!

Joe--
I thought of a couple things to ask--maybe they're repetitive, so my apologies (I only have a moment this monring).

1. Please comment on the preventative properties of Tykerb with respect to brain mets. Do they feel there is value in taking the drug in situations where there is a high probability of brain mets?

2. Please comment on the value of Tykerb when taken by iteself. What do you feel that the difference in Tykerb's efficacy when (1) taken by itself, and (2) combined with other drugs (which ones)?

thanks!
Val

Joe,
Since in an other post you say that GSK is not going to answer many of the questions in this thread which go beyond the FDA appoval criteria, could you get some responses from oncs not tied to GSK?